Evidence map›Paper›PMID 39458423›Full record

ReviewNutrients2024

Acute Sarcopenia: Mechanisms and Management.

Sarah Damanti, Eleonora Senini, Rebecca De Lorenzo, Aurora Merolla, Simona Santoro, Costanza Festorazzi, Marco Messina, Giordano Vitali, Clara Sciorati, Patrizia Rovere-Querini

Abstract readReview
In one paragraph

Review in Nutrients, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sarah DamantiInternal Medicine Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.ORCID 0000-0002-2399-3688
Eleonora SeniniDivision of Immunology, Transplantation and Infectious Diseases, Vita-Salute San Raffaele University, 20100 Milan, Italy.
Rebecca De LorenzoDivision of Immunology, Transplantation and Infectious Diseases, Vita-Salute San Raffaele University, 20100 Milan, Italy.
Aurora MerollaDivision of Immunology, Transplantation and Infectious Diseases, Vita-Salute San Raffaele University, 20100 Milan, Italy.ORCID 0009-0000-3584-4754
Simona SantoroDivision of Immunology, Transplantation and Infectious Diseases, Vita-Salute San Raffaele University, 20100 Milan, Italy.
Costanza FestorazziDivision of Immunology, Transplantation and Infectious Diseases, Vita-Salute San Raffaele University, 20100 Milan, Italy.
Marco MessinaDivision of Immunology, Transplantation and Infectious Diseases, Vita-Salute San Raffaele University, 20100 Milan, Italy.
Giordano VitaliInternal Medicine Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
Clara ScioratiDivision of Immunology, Transplantation and Infectious Diseases, Vita-Salute San Raffaele University, 20100 Milan, Italy.ORCID 0000-0003-2030-9366
Patrizia Rovere-QueriniInternal Medicine Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.

Funding

European Union - Next Generation EU - NRRP M6C2 - Investment 2.1 Enhancement and strengthening of biomedical research in the NHS PNRR-MAD-2022-12376672
6 · The paper itself

Abstract

backgroundAcute sarcopenia refers to the swift decline in muscle function and mass following acute events such as illness, surgery, trauma, or burns that presents significant challenges in hospitalized older adults.

methodsnarrative review to describe the mechanisms and management of acute sarcopenia.

resultsThe prevalence of acute sarcopenia ranges from 28% to 69%, likely underdiagnosed due to the absence of muscle mass and function assessments in most clinical settings. Systemic inflammation, immune-endocrine dysregulation, and anabolic resistance are identified as key pathophysiological factors. Interventions include early mobilization, resistance exercise, neuromuscular electrical stimulation, and nutritional strategies such as protein supplementation, leucine, β-hydroxy-β-methyl-butyrate, omega-3 fatty acids, and creatine monohydrate. Pharmaceuticals show variable efficacy.

conclusionsFuture research should prioritize serial monitoring of muscle parameters, identification of predictive biomarkers, and the involvement of multidisciplinary teams from hospital admission to address sarcopenia. Early and targeted interventions are crucial to improve outcomes and prevent long-term disability associated with acute sarcopenia.

Indexed as

SarcopeniaAcute DiseaseAgedDietary SupplementsHumansMuscle, Skeletalacute sarcopeniahospitalizationmuscle wasting

Identifiers

PMID39458423
PMCPMC11510680

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.